Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA BLADDR 2021 | New agents and novel trials in advanced UC

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses new agents and novel trials in advanced urothelial carcinoma (UC), including the use of antibody-drug conjugates, FGFR inhibitors and the promise of combination therapies and biomarkers. This interview took place at the PROSCA/BLADDR 2021 congress.